We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-11.57%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.66B
AUM Growth
-$569M
Cap. Flow
-$51.7M
Cap. Flow %
-3.12%
Top 10 Hldgs %
63.62%
Holding
67
New
7
Increased
4
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$33.9M
2
IOBT
IO Biotech
IOBT
+$29.1M
3
RLMD icon
Relmada Therapeutics
RLMD
+$19.6M
4
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
+$15.8M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$9.34M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$47.3M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$37.3M
3
LEGN icon
Legend Biotech
LEGN
+$12.4M
4
CRIS icon
Curis
CRIS
+$12.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 86.32%
2 Financials 9.88%
3 Materials 3.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
26
Olema Pharmaceuticals
OLMA
$999M
$15.8M 0.95%
1,689,515
+450,940
+36% +$9.34M
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14.2M 0.86%
872,151
– –
MRUS
28
DELISTED
Merus
MRUS
$14.1M 0.85%
442,000
– –
ACRS icon
29
Aclaris Therapeutics
ACRS
$789M
$13.4M 0.81%
920,982
-19,772
-2% -$300K
SERA icon
30
Sera Prognostics
SERA
$82.2M
$12.8M 0.77%
1,856,011
– –
CDXS icon
31
Codexis
CDXS
$158M
$12.1M 0.73%
388,144
– –
LEGN icon
32
Legend Biotech
LEGN
$3.69B
$11.4M 0.69%
244,375
-244,376
-50% -$12.4M
UTRS
33
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$11.4M 0.69%
+110,783
New +$15.8M
DSGN icon
34
Design Therapeutics
DSGN
$797M
$11.4M 0.69%
530,991
– –
MREO
35
Mereo BioPharma
MREO
$51.3M
$11.1M 0.67%
6,907,189
– –
ZLAB icon
36
Zai Lab
ZLAB
$2.08B
$11M 0.66%
174,999
– –
EPIX
37
DELISTED
ESSA Pharma
EPIX
$10.6M 0.64%
744,058
-312,009
-30% -$3.48M
ARWR icon
38
Arrowhead Research
ARWR
$12.3B
$9.11M 0.55%
137,411
– –
DICE
39
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$8.26M 0.5%
326,272
-83,728
-20% -$2.45M
BLU
40
DELISTED
BELLUS Health Inc.
BLU
$8.19M 0.49%
+1,017,152
New +$6.75M
NKTX icon
41
Nkarta
NKTX
$158M
$7.86M 0.47%
512,225
– –
DYN icon
42
Dyne Therapeutics
DYN
$4.78B
$6.87M 0.41%
577,642
– –
CMPX icon
43
Compass Therapeutics
CMPX
$348M
$6.34M 0.38%
+2,000,000
New +$6.63M
GRCL
44
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$5.81M 0.35%
961,359
– –
IOVA icon
45
Iovance Biotherapeutics
IOVA
$1.94B
$5.75M 0.35%
+301,000
New +$6.63M
STSA
46
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$5.55M 0.33%
1,232,394
– –
ZYME icon
47
Zymeworks
ZYME
$1.64B
$4.69M 0.28%
286,064
– –
LRMR icon
48
Larimar Therapeutics
LRMR
$404M
$4.31M 0.26%
399,830
– –
ASLN
49
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$3.18M 0.19%
71,023
– –
QTTB icon
50
Q32 Bio
QTTB
$452M
$3.1M 0.19%
47,397
– –
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Vivo Capital held 67 positions worth $1.66B, down 26% from $2.23B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital withdrew a net $51.7M in Q4 2021, closing 12 positions and reducing 8 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $37.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Ventyx Biosciences worth $35.6M.

  • Vivo Capital's largest Q4 2021 buy was Ventyx Biosciences: 1,791,275 shares worth $35.6M.
  • Vivo Capital added most to Olema Pharmaceuticals in Q4 2021, an estimated $9.34M increase.
  • Vivo Capital's biggest Q4 2021 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
  • Vivo Capital fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $37.3M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.66B portfolio in Q4 2021.
  • Vivo Capital opened 7 new positions and closed 12 in Q4 2021.
  • Vivo Capital's portfolio value fell 26% quarter-over-quarter to $1.66B.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.